[go: up one dir, main page]

MX2012007940A - Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. - Google Patents

Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.

Info

Publication number
MX2012007940A
MX2012007940A MX2012007940A MX2012007940A MX2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A MX 2012007940 A MX2012007940 A MX 2012007940A
Authority
MX
Mexico
Prior art keywords
bevacizumab
mcrc
combined
biomarcators
tumor
Prior art date
Application number
MX2012007940A
Other languages
English (en)
Inventor
Dorothee Foernzler
Paul Delmar
Stefan Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012007940A publication Critical patent/MX2012007940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G01N33/575—
    • G01N33/5753—
    • G01N33/57535—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para mejorar la superviviencia libre de progresión de un paciente que padece de cáncer gastrointestinal, en particular, cáncer colorrectal metastásico (mCRC), por el tratamiento con bevacizumab (Avastin(r)) combinado con una posología de quimioterapia al determinar el nivel de expresión de uno o más de VEGFA, HER2 y neuropilina con relación a niveles control en pacientes diagnosticados con cáncer gastrointestinal, en particular, cáncer colorrectal metastásico (mCRC) La presente invención adicionalmente proporciona los métodos para evaluar la sensibilidad o susceptibilidad de un paciente a bevacizumab (Avastin(r)) combinado con una posología de quimioterapia, al determinar el nivel de expresión de uno o más de VEGFA, HER2 y neuropilina con relación a niveles control en pacientes diagnosticados con cáncer gastrointestinal, en particular, cáncer colorrectal metastásico (mCRC).
MX2012007940A 2010-01-19 2011-01-18 Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab. MX2012007940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151109 2010-01-19
PCT/EP2011/050564 WO2011089101A1 (en) 2010-01-19 2011-01-18 Tumor tissue based biomarkers for bevacizumab combination therapies

Publications (1)

Publication Number Publication Date
MX2012007940A true MX2012007940A (es) 2012-08-03

Family

ID=43770611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007940A MX2012007940A (es) 2010-01-19 2011-01-18 Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.

Country Status (16)

Country Link
US (2) US20110182892A1 (es)
EP (2) EP2525821A1 (es)
JP (2) JP6057718B2 (es)
KR (1) KR101523419B1 (es)
CN (2) CN104474545A (es)
AU (1) AU2011208805A1 (es)
BR (1) BR112012016229A2 (es)
CA (2) CA2891047A1 (es)
HK (1) HK1208804A1 (es)
IL (1) IL220084A (es)
MX (1) MX2012007940A (es)
MY (1) MY172580A (es)
RU (1) RU2605282C2 (es)
SG (2) SG10201500479XA (es)
WO (1) WO2011089101A1 (es)
ZA (1) ZA201205014B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2806447A1 (en) * 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Neuropilin as a biomarker for bevacizumab combination therapies
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
US9116159B2 (en) 2012-05-22 2015-08-25 Regeneron Pharmaceuticals, Inc. VEGF-A121 assay
EP3108255B1 (en) * 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
EA036671B1 (ru) 2014-09-16 2020-12-07 Ридженерон Фармасьютикалз, Инк. Способ лечения и диагностики метастатического колоректального рака на основании уровня vegf-a
CA2966216A1 (en) * 2014-11-14 2016-05-19 Genentech, Inc. Predicting response to a vegf antagonist
WO2016115149A1 (en) * 2015-01-12 2016-07-21 Aveo Pharmaceuticals, Inc. Neuropilin-1 as a serum based biomarker
CN104531714A (zh) * 2015-01-23 2015-04-22 香港中文大学深圳研究院 适用于植物表达体系的表达贝伐单抗的基因、重组载体及产贝伐单抗植物的构建方法及应用
CN105424682A (zh) * 2015-11-17 2016-03-23 苏州浩欧博生物医药有限公司 一种贝伐单抗试剂盒及其抗药抗体试剂盒
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
GR1009946B (el) * 2019-06-25 2021-03-04 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Οι συγκεντρωσεις της μπεβασιζουμαμπης σαν δεικτης στην ανταποκριση στη θεραπεια και στη συνολικη επιβιωση
RU2740361C1 (ru) * 2020-07-31 2021-01-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ органосохраняющего лечения операбельного рака прямой кишки

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275057A1 (en) * 2006-03-31 2009-11-05 Linke Steven P Diagnostic markers predictive of outcomes in colorectal cancer treatment and progression and methods of use thereof
AU2008205488A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms in VEGF and VEGF receptor 2 as markers for cancer therapy
WO2008088854A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Genetic markers for predicting responsiveness to combination therapy

Also Published As

Publication number Publication date
US20110182892A1 (en) 2011-07-28
CA2891047A1 (en) 2011-07-18
RU2012133472A (ru) 2014-02-27
EP2525821A1 (en) 2012-11-28
JP2013517258A (ja) 2013-05-16
IL220084A0 (en) 2012-09-24
IL220084A (en) 2016-11-30
AU2011208805A1 (en) 2012-06-21
JP6057718B2 (ja) 2017-01-11
ZA201205014B (en) 2013-03-27
KR20120123426A (ko) 2012-11-08
WO2011089101A1 (en) 2011-07-28
SG10201500479XA (en) 2015-03-30
CN104474545A (zh) 2015-04-01
MY172580A (en) 2019-12-04
JP2015178500A (ja) 2015-10-08
SG182520A1 (en) 2012-08-30
KR101523419B1 (ko) 2015-05-27
HK1208804A1 (en) 2016-03-18
EP2857040A1 (en) 2015-04-08
US20140099302A1 (en) 2014-04-10
CN102711830A (zh) 2012-10-03
BR112012016229A2 (pt) 2017-03-07
RU2605282C2 (ru) 2016-12-20
CA2785774A1 (en) 2011-07-18

Similar Documents

Publication Publication Date Title
MX2012007940A (es) Biomarcadores basados en tejido tumoral para terapias combinadas con bevacizumab.
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
AR089067A1 (es) Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
MX369106B (es) Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo.
AR060228A1 (es) Diagnosticos y tratamientos para tumores
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
MX365418B (es) Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CY1121821T1 (el) Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
EA201301265A1 (ru) Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
MX2015017950A (es) Metodos para el tratamiento de cancer de ovario.
CO6612209A2 (es) Terapia antia-agiogénesis para el tratamiento de cáncer de mama previamente tratado
WO2012020123A3 (en) Neuropilin as a biomarker for bevacizumab combination therapies
MX2017006201A (es) Respuesta de prediccion a un antagonista de vegf.
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
WO2014066860A3 (en) Methods of prognosticating and treating cancer